Authors
Latest:
Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1ABSTRACT Advances in immuno-oncology over the last several years have led to FDA approvals of novel agents. As our understanding of immune response and its checkpoints has evolved, further advances have been made in treatment for several cancer types. To predict a response to immunotherapy, the initial biomarkers used were expression of the PD-1 receptor and PD-L1, as assessed by immunohistochemistry. More recently, predictive biomarkers have included microsatellite instability, DNA mismatch repair, and tumor mutational burden. Although these markers may be clinically relevant in predicting an immunotherapy response, cancer immunotherapy fails some patients. Improved understanding of the human immune system is necessary, as is a careful evaluation of the methods used to predict and assess response to Immuno-oncology treatments. With the application of therapeutic immune-modulating agents, more comprehensive assays, and associated bioinformatics tools to accurately assess the tumor microenvironment, we may better predict responses to immuno-oncology agents and the ever-increasing complexity of their clinical use.
Latest:
Unusual Initial Presentation of Hepatocellular Carcinoma as a Clavicular Head MassRohit Gupta, MD, et al review a case study of a 70-year-old man who presented with a head mass, and the final diagnosis was hepatocellular carcinoma.
Latest:
Integrating PARP Inhibitors Into Advanced Prostate Cancer TherapeuticsExperts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.
Latest:
Sattva S. Neelapu, MD, Discusses Further ZUMA-5 Follow-up on Axi-Cel for R/R iNHLSattva S. Neelapu, MD, spoke about continuing to look at results from the ZUMA-5 trial to determine if axicabtagene ciloleucel can cure patients with relapsed or refractory indolent non-Hodgkin lymphoma
Latest:
Affirming the Feasibility of cfDNA Sequencing Use in Li-Fraumeni SyndromeSubsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
Latest:
Challenges in Optimizing Sequencing Strategies in R/R MMExperts on multiple myeloma outline current challenges in determining the optimal treatment strategy for patients with relapsed/refractory disease who are eligible for bispecifics and CAR T-cell therapy.
Latest:
Managing 3rd-Line R/R FL: Recognizing Progression, Performing Rebiopsies, and Rechecking for CD20 PositivityPanelists discuss how rebiopsy and CD20 reassessment at suspected progression of follicular lymphoma after second-line therapy are critical for detecting histologic transformation, evaluating changes in disease biology, and informing the selection of appropriate third-line treatment strategies.
Latest:
Asciminib May Be an “Attractive” Option in Newly Diagnosed CML PopulationsOngoing genomic profiling analyses in the ASC4FIRST trial may further determine which patients with CML may benefit from treatment with asciminib.
Latest:
Yael Cohen, MD, on Entering an Era of CAR T-Cell Therapy for MyelomaYael Cohen, MD, sat down with CancerNetwork® to discuss how the multiple myeloma space is entering into an era of CAR T-cell therapy.
Latest:
The COLOMATE Platform: An Indispensable Initiative Promoting True Precision Oncology Prioritized for Patients With Cancer—From “MAYBE” to “MUST BE”Takayuki Yoshino, MD, PhD provides perspective on key issues surrounding therapy selection in gastrointestinal cancers.
Latest:
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous RituximabRituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.
Latest:
Advancing Thoracic Surgery With Robotics and Video-Assisted Strategies"Anything that you can do to leverage technology to minimize the variability in surgery eliminates the skill gap so that novice surgeons may become as technically gifted as the intermediate surgeon or the master surgeon."
Latest:
Treatment of Locally Advanced Cervical Cancer With Kidney Failure and ComorbiditiesIn this edition of Clinical Quandaries Eder A. Arango Bravo, MD, and colleagues present a 63 year old woman who has cervical cancer with kidney failure and additional comorbidities.
Latest:
Clinical Pearls about the Referral Process of Bispecifics and CAR-T in RRMMThe discussion shares key takeaways and practical insights for optimizing the referral and treatment process for CAR T-cell and bispecific therapies.
Latest:
Evolving Treatment Landscape of RCC: Future Directions in CareClosing out their program on renal cell carcinoma management, key opinion leaders share closing thoughts on emerging therapies and how the field is evolving.
Latest:
Role of Neurooncologists in Management of HER2+ Breast Cancer and Brain MetastasesA look at the evolving role of neurooncologists in the treatment of patients with HER2+ breast cancer and brain metastases and future perspectives in the management of this patient population.
Latest:
How to Treat Metastatic Malignant Triton Tumor in an AdolescentA systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.
Latest:
Pancreatic Neuroendocrine Tumor With Humoral Hypercalcemia and High Tumor PD-L1 ScoreAbstract: Pancreatic neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms. They can be functioning tumors with secretion of a variety of peptide hormones, or nonfunctioning tumors with metastases to the liver at the time of diagnosis. Well-differentiated tumors tend to be slow-growing and characterized by low tumor mutational burden (TMB) and lower propensity to express PD-L1. Hypercalcemia due to malignancy can occur in about 20% to 30% of patients with cancer. The secretion of parathyroid hormone–related protein (PTH-rP) is among the causes of malignant hypercalcemia and has seldom been associated with hypercalcemia of NETs. Although the therapeutic landscape for neuroendocrine neoplasms has evolved substantially over the past decade, the role of immunotherapy has not yet been completely explored in this group of patients. We present a rare case of a metastatic pancreatic NET with high TMB, high PD-L1 tumor proportion score, and high PTH-rP–related hypercalcemia.
Latest:
Clinical Limit of Detection May Represent Viable cfDNA Metric For Detection of Multiple CancersData from the Circulating Cell-Free Genome Atlas on Clinical limit of detection, or cLOD, may help investigators better detect multiple cancers at earlier stages.
Latest:
Neoadjuvant Vs Adjuvant Treatment Strategies for Ovarian CancerSurgery followed by platinum-based chemotherapy may provide the most benefit for patients with ovarian cancer, according to a medical oncologist.
